Nectero Medical recently announced that the American Medical Association’s CPT editorial panel has approved two category III CPT codes applicable to the Nectero endovascular aneurysm stabilisation treatment (EAST) system procedure via a percutaneous or open approach. The company notes in a press release that this designation represents a key milestone toward future reimbursement and broader clinical adoption.
“This approval is a meaningful step forward in validating our technology and preparing for reimbursement,” said Jack Springer, president and chief executive officer of Nectero Medical. “It reflects extensive collaboration with multiple medical societies to build consensus and define the procedure accurately.”
Category III CPT codes are designated for emerging technologies, services, and procedures. The two newly approved codes will facilitate physician and hospital billing and reimbursement for treatment with the Nectero EAST system in clinical practice.
The Nectero EAST system is currently being evaluated in the investigational new drug (IND) phase II/III stAAAble study, a multicentre, randomised clinical trial assessing safety and efficacy in patients with small- to medium-sized abdominal aortic aneurysms (AAAs). The IND submission was supported by a prospective, first-in-human study of 46 patients treated outside the USA, which demonstrated that a single, localised administration of pentagalloylglucose (PGG) was safe and showed the potential to slow aneurysm growth. One-year follow-up results on the full cohort of patients from this study were recently presented at the Charing Cross (CX) Symposium (23–25 April, London, UK). The data showed a significant reduction in aneurysm diameter growth compared to historical control data, with 91% of patients growing at less than the expected growth rate.
